StreetAlpha.app
Home › Stocks › PHVS

Pharvaris N.V. (PHVS)

Healthcare
$32.28
▼ −0.49%
LAST CLOSE · NOV 17

Pharvaris develops drug candidates for hereditary angioedema, a rare condition that causes episodes of severe swelling. It last closed at $32.28 on Nov 17, down 0.49% on the day. The average 12-month price target from 9 analysts is $59.00 (+82.8% from the last close), with a high of $79.00 and a low of $44.00. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (9 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in PHVS, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is PHVS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−EUR 175.7M
Free cash flow
−EUR 137.2M
Balance sheet
Cash & equivalents
EUR 291.7M
At Dec 31
Shareholder equity
EUR 271.3M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −EUR 42.7M−EUR 42.7MFY2021FY2022: −EUR 76.3M−EUR 76.3MFY2022FY2023: −EUR 100.9M−EUR 100.9MFY2023FY2024: −EUR 134.2M−EUR 134.2MFY2024FY2025: −EUR 175.7M−EUR 175.7MFY2025

From PHVS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Apr 2). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 9 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
9firms
9 Buy0 Hold0 Sell
Each firm's latest rating on PHVS in the past 90 days
Average 12-month target
$59.00
▲ 82.8% upside

Based on 9 analysts who set a price target on PHVS in the past 90 days. The average target is $59.00, with a high of $79.00 and a low of $44.00, compared with the last close of $32.28.

Low $44.00Avg $59.00High $79.00
Blue marker: last close $32.28
Highest target$79.00
Average target$59.00
Lowest target$44.00
Latest rating changes
B of A SecuritiesUpgrade
Oct 23Buy$44
GuggenheimTarget raised
Sep 10Buy$40 → $44
Morgan StanleyMaintained
Sep 9Buy$62
Leerink PartnersMaintained
Sep 9Buy$65
Wells FargoTarget raised
Sep 9Buy$55 → $65
DateFirmActionRatingPrice target
Oct 23B of A SecuritiesUpgradeBuy$44
Sep 10GuggenheimTarget raisedBuy$40 → $44
Sep 9Morgan StanleyMaintainedBuy$62
Sep 9Leerink PartnersMaintainedBuy$65
Sep 9Wells FargoTarget raisedBuy$55 → $65
Loading…

Technical Analysis

PHVS · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 2% below its 20 day and 2% below its 50 day average. It is 3% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 46). The nearest support is the Pivot at $32.00, and the nearest resistance the swing high (Oct 7) at $32.32.

Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 4.7%/day
Key levels
$43.2552 week high+34.0%
$33.97100 day average+5.2%
$33.0750 day average+2.4%
$33.0120 day average+2.3%
$32.70Pivot R1+1.3%
$32.32Swing high (Oct 7)+0.1%
$32.28Last close
$32.00Pivot−0.9%
$31.57Pivot S1−2.2%
$31.51Swing low (Aug 3)−2.4%
$31.39200 day average−2.8%
$23.0152 week low−28.7%
Indicators
RSI (14)45.89Middle of its rangeNeutral
MACD0.25Below its signal lineBearish
Stochastic29.4Middle of its rangeNeutral
ADX (14)15.0No clear trend
Williams %R-76.3Oversold below −80, overbought above −20Neutral
CCI (20)-66.0Oversold below −100, overbought above 100Neutral
Rate of change−7.2%Change over 10 sessionsBearish
ATR (14)$1.52Typical daily range, 4.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for PHVS

What happened before

See how PHVS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PHVS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PHVS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 2 – Sep 2
Loading…

See today’s whale options flow across the market →

PHVS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲80 buying vs 47 selling
  • ▲Shares held by funds +3.8%
  • ▲Funds holding +10
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding135125+8.0%
In funds' top 101514+7.1%
Held by funds–––
New / increased22 / 5823 / 47+14.3%
Reduced / sold out34 / 1333 / 10+9.3%
Put/call ratio1.39––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PHVS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PHVS is in one of them and how their past PHVS trades turned out.

PHVS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PHVS in an article yet. Here's the latest on the wider market.

About Pharvaris N.V.

Pharvaris is a pharmaceutical company based in Leiden that is developing treatments for hereditary angioedema, a rare condition that causes episodes of severe swelling. Its product candidates, including IR and XR, are still in clinical development and have not yet received marketing approval. If approved, they would be sold to patients and physicians, with insurers and other payors deciding how much coverage to provide. The company intends them to be used alongside or in place of existing therapies.

Headquarters
Leiden